PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-143.14%
Negative EBIT growth while TRVN is at 11.91%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
5.86%
Operating income growth under 50% of TRVN's 11.91%. Michael Burry would be concerned about deeper cost or sales issues.
-142.73%
Negative net income growth while TRVN stands at 10.91%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-120.58%
Negative EPS growth while TRVN is at 14.32%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-120.58%
Negative diluted EPS growth while TRVN is at 14.32%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
10.21%
Share count expansion well above TRVN's 3.97%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
10.21%
Diluted share count expanding well above TRVN's 3.97%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
9.39%
Positive OCF growth while TRVN is negative. John Neff would see this as a clear operational advantage vs. the competitor.
9.37%
Positive FCF growth while TRVN is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-56347.73%
Negative 10Y OCF/share CAGR while TRVN stands at 19.42%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-5186.83%
Negative 5Y OCF/share CAGR while TRVN is at 19.42%. Joel Greenblatt would question the firm’s operational model or cost structure.
-34380.15%
Negative 3Y OCF/share CAGR while TRVN stands at 19.42%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-67208.18%
Negative 10Y net income/share CAGR while TRVN is at 17.02%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-8163.79%
Negative 5Y net income/share CAGR while TRVN is 17.02%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-121.82%
Negative 3Y CAGR while TRVN is 17.02%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
31995.75%
Positive growth while TRVN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
9371.92%
Positive 5Y equity/share CAGR while TRVN is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
10880.98%
Positive short-term equity growth while TRVN is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
31.29%
Asset growth above 1.5x TRVN's 4.64%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
28.45%
BV/share growth above 1.5x TRVN's 2.35%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-51.38%
We’re deleveraging while TRVN stands at 1.64%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-5.21%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-6.73%
We cut SG&A while TRVN invests at 0.57%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.